Blood Volume Analysis Coupled with Ultrafiltration in the Management of Congestive Heart Failure - Guided Therapy to Achieve Euvolemia


Abnormal regulation of intravascular volume plays a key role in the pathophysiology of heart failure. Expert consensus guidelines recommend treating volume-overloaded heart failure patients with lifestyle modifications and diuretics to return them to a euvolemic (normovolemic) state. The diagnosis of volume overload can be imprecise, as previous studies have shown that signs of congestion detected by physical examination and chest radiography are inaccurate markers of fluid excess. The most direct and accurate method available for determination of intravascular volume status is radioisotopic measurement using the indicator dilution method. This technique can be applied to clinical decision-making in heart failure patients and may be used to more precisely guide fluid removal by ultrafiltration such that patients are restored to euvolemia with minimal risk.

The author wishes to thank Sandy Gilbert, PhD, for her editorial assistance with this manuscript.


Volume Overload in Heart Failure

The burden of heart failure (HF) remains formidable in the US, with nearly one million annual hospital admissions and frequent outpatient visits to a variety of care providers.1 While HF outcomes have improved modestly over the past several decades, many patients still struggle to maintain a satisfactory quality of life.2 Implantable cardioverter– defibrillators have reduced the risk for sudden cardiac death. Thus, more patients experience progressive ventricular dysfunction and are at higher risk for episodes of fluid retention. In fact, fluid retention is the primary presenting symptom in roughly 90% of the one million annual hospitalizations for HF.3
Diuretics are the most commonly prescribed medical therapy for hospitalized HF patients.3 Diuretics are prescribed out of necessity, although they are associated with worse outcomes in both inpatient and outpatient settings.4 It is a major challenge to determine when an HF patient has achieved euvolemia (normovolemia) and to adjust diuretic therapy appropriately. Recently published guidelines from the American College of Cardiology (ACC), the American Heart Association (AHA), the Heart Failure Society of America (HFSA), and the European Society of Cardiology (ESC) recommend regular volume assessment of HF patients coupled with therapy aimed at achieving euvolemia.1,5,6
Salt and water retention in HF is due, in part, to neurohormonal activation of the renin–angiotensin–aldosterone system (RAAS) and increased vasopressin levels. Suboptimal patient adherence to and compliance with medical therapy and dietary restrictions also contribute to volume overload.7 Almost 25% of discharged HF patients are re-hospitalized within 30 days, many for recurrent volume overload.8 Inadequate correction of hypervolemia at the initial admission may account for some of this elevated risk, while poor patient compliance and suboptimal co-ordination of care at discharge likely explain the remaining residual risk.9–12
What is lacking in the routine care of the HF patient is a more systematic approach to guide fluid management therapy by helping clinicians to determine when patients have achieved normovolemia. This article will highlight this unmet need and explore the use of quantitative blood volume analysis (BVA) as a tool to guide management of volume overload in HF patients.


  1. Jessup M, et al., 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation, Circulation, 2009;119(14):1977–2016.
  2. Levy D, et al., Long-term trends in the incidence of and survival with heart failure, N Engl J Med, 2002;347(18): 1397–1402.
  3. Adams KF Jr., et al., Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE), Am Heart J, 2005;149(2):209–16.
  4. Knight EL, et al., Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD), Am Heart J, 1999;138(5 Pt 1): 849–55.
  5. Executive summary, HFSA 2006 Comprehensive Heart Failure Practice Guideline, J Card Fail, 2006;12(1):10–38.
  6. Dickstein K, et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail, 2008;10(10):933–89.
  7. West JA, et al., A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization, Am J Cardiol, 1997;79(1):58–63.
  8. Krumholz HM, et al., Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission, Circ Cardiovasc Qual Outcomes, 2009;2(5):407–13.
  9. Hamner JB, Ellison KJ, Predictors of hospital readmission after discharge in patients with congestive heart failure, Heart Lung, 2005;34(4):231–9.
  10. Tsuchihashi M, et al., Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure, Am Heart J, 2001;142(4):E7.
  11. Krumholz HM, et al., Predictors of readmission among elderly survivors of admission with heart failure, Am Heart J, 2000;139(1 Pt 1):72–7.
  12. Maska E, et al., A novel heart failure disease management strategy reduces heart failure readmissions in veterans with Heart Failure, J Cardiac Fail, 2009;15(6S):S115.
  13. Gottlieb SS, et al., BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy, Circulation, 2002;105(11):1348–53.
  14. Cooper HA, et al., Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction, Circulation, 1999;100(12):1311–15.
  15. Bayliss J, et al., Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics, Br Heart J, 1987;57(1):17–22.
  16. Iyengar S, Abraham WT, Diuretic resistance in heart failure, Curr Heart Fail Rep, 2006;3(1):41–5.
  17. Ellison DH, Diuretic therapy and resistance in congestive heart failure, Cardiology, 2001;96(3–4):132–43.
  18. De Bruyne LK, Mechanisms and management of diuretic resistance in congestive heart failure, Postgrad Med J, 2003;79(931):268–71.
  19. Agostoni P, et al., Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result, Am J Med, 1994;96(3):191–9.
  20. Agostoni PG, Marenzi GC, Sustained benefit from ultrafiltration in moderate congestive heart failure, Cardiology, 2001;96(3–4):183–9.
  21. Bart BA, et al., Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial, J Am Coll Cardiol, 2005;46(11):2043–6.
  22. Costanzo MR, et al., Early ultrafiltration in patients with decompensated heart failure and diuretic resistance, J Am Coll Cardiol, 2005;46(11):2047–51.
  23. Sheppard R, et al., Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure, J Card Fail, 2004;10(5):380–83.
  24. Costanzo MR, et al., Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure, J Am Coll Cardiol, 2007;49(6):675–83.
  25. Chakko S, et al., Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care, Am J Med, 1991;90(3):353–9.
  26. Butman SM, et al., Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension, J Am Coll Cardiol, 1993;22(4):968–74.
  27. Androne AS, et al., Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes, Am J Cardiol, 2004;93(10):1254–9.
  28. Dworkin HJ, Premo M, Dees S, Comparison of red cell and whole blood volume as performed using both chromium-51- tagged red cells and iodine-125-tagged albumin and using I- 131-tagged albumin and extrapolated red cell volume, Am J Med Sci, 2007;334(1):37–40.
  29. Manzone TA, et al., Blood volume analysis: a new technique and new clinical interest reinvigorate a classic study, J Nucl Med Technol, 2007;35(2):55–63, quiz 77, 79.
  30. Feldschuh J, Enson Y, Prediction of the normal blood volume. Relation of blood volume to body habitus, Circulation, 1977;56(4 Pt 1):605–12.
  31. Gheorghiade M, et al., Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial, JAMA, 2004;291(16): 1963–71.
  32. Marenzi G, et al., Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure, J Am Coll Cardiol, 2001;38(4): 963–8.
  33. Boyle A, Sobotka PA, Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate, J Card Fail, 2006;12(4):247–9.
  34. Androne AS, et al., Hemodilution is common in patients with advanced heart failure, Circulation, 2003;107(2):226–9.
  35. Fonay K, Zambo K, Radnai B, [The effect of high blood viscosity, caused by secondary polycythemia, on pulmonary circulation and gas exchange in patients with chronic cor pulmonale], Orv Hetil, 1994;135(19):1017–21.